Healthcare provider profile · identity verified

Hannah Sung Hee Sim, MD

Internal Medicine · BALDWIN PARK, CA · NPI 1811036510

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	512	187
Amlodipine Besylate	Amlodipine Besylate	380	138
Lisinopril	Lisinopril	295	106
Losartan Potassium	Losartan Potassium	268	98
Levothyroxine Sodium	Levothyroxine Sodium	227	83
Simvastatin	Simvastatin	180	64
Rosuvastatin Calcium	Rosuvastatin Calcium	175	70
Atenolol	Atenolol	163	58
Omeprazole	Omeprazole	146	68
Glipizide	Glipizide	142	54
Metformin Hcl Er	Metformin Hcl	142	53
Metformin Hcl	Metformin Hcl	140	53
Alendronate Sodium	Alendronate Sodium	131	49
Metoprolol Tartrate	Metoprolol Tartrate	122	46
Humulin N Kwikpen	Insulin Nph Human Isophane	103	34
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	102	30
Jardiance	Empagliflozin	88	33
Meloxicam	Meloxicam	84	44
Hydrochlorothiazide	Hydrochlorothiazide	83	33
Terazosin Hcl	Terazosin Hcl	61	23
Albuterol Sulfate Hfa	Albuterol Sulfate	56	32
Gabapentin	Gabapentin	54	19
Pradaxa	Dabigatran Etexilate Mesylate	54	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	16
Pantoprazole Sodium	Pantoprazole Sodium	49	17
Potassium Chloride	Potassium Chloride	47	17
Fluoxetine Hcl	Fluoxetine Hcl	43	16
Clopidogrel	Clopidogrel Bisulfate	41	16
Finasteride	Finasteride	40	18
Furosemide	Furosemide	38	18
Hydralazine Hcl	Hydralazine Hcl	37	21
Pravastatin Sodium	Pravastatin Sodium	37	13
Tramadol Hcl	Tramadol Hcl	35	14
Humulin N	Insulin Nph Human Isophane	32	11
Montelukast Sodium	Montelukast Sodium	31	11
Fenofibrate	Fenofibrate	29	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	29	14
Humulin R	Insulin Regular, Human	28	suppressed
Ibuprofen	Ibuprofen	28	16
Allopurinol	Allopurinol	27	suppressed
Alvesco	Ciclesonide	25	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	11
Benazepril Hcl	Benazepril Hcl	24	suppressed
Carvedilol	Carvedilol	24	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Famotidine	Famotidine	23	11
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Latanoprost	Latanoprost	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	12
Humalog Kwikpen U-100	Insulin Lispro	21	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Sertraline Hcl	Sertraline Hcl	20	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	19	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Eliquis	Apixaban	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	18	suppressed
Colchicine	Colchicine	16	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Prednisone	Prednisone	16	15
Spiriva Respimat	Tiotropium Bromide	16	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Alprazolam	Alprazolam	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Naproxen	Naproxen	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Estradiol	Estradiol	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Pimecrolimus	Pimecrolimus	12	suppressed
Cefadroxil	Cefadroxil	11	11
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error